Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$1.82 +3.68%

+$0.13 today

Market cap
$68.52M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.30M

Average 0.21M

ADAG Sales of Investments

Cash received from selling or redeeming investments.

Adagene Inc.NASDAQ: ADAG

Sales of Investments · Q4 FY2025 · quarter ended Dec 2025

Sales of investments dips below year-ago levels

Q4 FY2025 sales of investments of $40.38M fell 68.9% year over year, behind the +100.0% change in trailing-twelve-month sales of investments.

Context

  • Sales of investments amounted to 1049.3% of revenue in FY2025, down 124569.4 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -68.9% toward the trailing-twelve-month pace of +100.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$40.38M— QoQ
Last fiscal yearDec 2025
$80.49M-37.9% YoY
LTMJun 2024
$0+100.0% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-68.9%——
1 year-37.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
80.49M USD
Year-over-year change
-37.9%

Sales of Investments vs competitors

How ADAG compares with its peers on the latest reported figures

  • ADAG's LTM Jun 2024 sales of investments of $0 is the 3rd largest of the 9 companies compared; the peer median is $0.
  • Sales of investments amounts to 0.0% of revenue for ADAG, versus a peer median of 0.0%.
ADAG Competitors Peer median
Sales of Investments for ADAG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$125.25M -43.8%—1371.0%
ACETAdicet Bio, Inc.LTM Mar 2026$83M +88.6%——
ADAGAdagene Inc.LTM Jun 2024$0 ——0.0%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
NTRBNutriband Inc.LTM Apr 2026$0 ——0.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$0 ——0.0%
XBITXBiotech Inc.LTM Mar 2026$0 ———
GANXGain Therapeutics, Inc.LTM Mar 2026$0 -100.0%——
OSTXOS Therapies IncorporatedLTM Mar 2026$0 ———
Peer median (excluding ADAG) $0-43.8%—0.0%

Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.18M)(79.97M)(18.95M)(33.42M)(17.61M)
Depreciation & Amortization1.13M1.45M1.21M926.25K589.79K
Deferred Income Tax622.43K(44.16K)000
Stock-Based Compensation18.68M10.52M7.27M4.91M3.74M
Change in Working Capital9.35M21.94M(16.55M)(1.89M)(775.3K)
Accounts Receivables(3M)6.89M397.41K213.72K(9.04K)
Inventory6.02M0000
Accounts Payables1.51M344.51K(572.37K)1.15M(1.36M)
Other Working Capital4.82M14.75M(16.38M)(3.25M)591.01K
Other Non-Cash Items(9.95K)(2.5M)(1.44M)(222.24K)(1.6M)
Operating Cash Flow(43.41M)(48.61M)(28.45M)(29.7M)(15.66M)
Capital Expenditures(2.51M)(690.94K)(85.01K)(33.58K)(17.05K)
Acquisitions (Net)00000
Purchases of Investments00(47M)(128.5M)(80M)
Sales of Investments0047M129.64M80.49M
Other Investing Activities04.89K7.66K1691.4K
Investing Cash Flow(2.51M)(686.05K)(77.36K)1.11M476.8K
Debt Repayment(702.86K)21.48M(5.37M)(3.42M)(12.24M)
Common Stock Issued149.79M05.5K7.33M138.28K
Common Stock Repurchased(2.36M)(3.98M)000
Dividends Paid00000
Other Financing Activities(1.37M)323.21K5.5K(137.3K)0
Financing Cash Flow145.36M17.82M(5.37M)3.77M4.45M
Effect of Forex Changes(192.35K)842.2K74.72K81.88K64.55K
Net Change in Cash99.24M(30.63M)(33.82M)(24.74M)(10.67M)
Free Cash Flow(45.92M)(49.3M)(28.54M)(29.73M)(15.67M)

Adagene Inc.

NASDAQ:ADAG

Intrinsic Alpha fair value

Locked

Current Price

$1.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.